Adaptive Biotechnologies Corporation, a biotechnology company focused on translating the genetics of the adaptive immune system into clinical products, will be presenting data at the Annual Meeting of the American Society of Hematology (ASH) in San Diego, California. The data, presented in over 30 abstracts, will showcase the effectiveness of Adaptive’s clonoSEQ test in assessing minimal residual disease (MRD) in blood cancer patients. MRD testing is a strong predictor of outcomes in blood cancers and provides personalized tracking of a patient’s response to treatment. Adaptive’s clonoSEQ is the only FDA-cleared test for MRD detection in certain blood cancer patients, and it is currently available for clinical use in Seattle, Washington.
Data from these abstracts will demonstrate the clinical actionability of MRD testing across disease states. The data will also highlight the growing role of MRD in blood cancer treatment and its impact on the development of new therapies. Notably, studies will showcase the prognostic value of cl
